Primal Health Databank: Study
| Entry No: | 0870 |
| Title: | Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Autism |
| Author(s): | Hviid A, Melbye M, et al. |
| Reference: | N Engl J Med 2013; 369:2406-2415December 19, 2013DOI: 10.1056/NEJMoa1301449 |
| Place of Study: | Denmark |
| Abstract: | This is a cohort study of all singleton live births in Denmark from 1996 through 2005 (626,875 births), with follow-up through 2009. Using Danish population registries, we linked information on maternal use of SSRIs before and during pregnancy, autism spectrum disorders diagnosed in the offspring, and a range of potential confounders. The authors used a survival analysis of the time to diagnosis in the offspring with Poisson regression to estimate rate ratios of autism spectrum disorders according to maternal use of SSRIs.
During 5,057,282 person-years of follow-up, the authors identified 3892 cases of autism spectrum disorder (incidence rate, 77.0 per 100,000 person-years). A total of 52 cases during 42,400 person-years of follow-up involved offspring of women who were exposed to SSRIs during their pregnancy (incidence rate, 122.6 per 100,000 person-years). As compared with no use of SSRIs both before and during pregnancy, use during pregnancy was not associated with a significantly increased risk of autism spectrum disorders (fully adjusted rate ratio, 1.20; 95% confidence interval [CI], 0.90 to 1.61). Among women who received SSRIs before pregnancy but not during pregnancy, the corresponding fully adjusted rate ratio was 1.46 (95% CI, 1.17 to 1.81).
Conclusions
this study did not detect a significant association between maternal use of SSRIs during pregnancy and autism spectrum disorder in the offspring. |
| Keyword(s): | antidepressant drugs, antidepressants, autism, autistic spectrum disorder, drugs in pregnancy |
| Discussion: | No discussion mentioned for this entry |
| See Also: | No related entries mentioned for this entry |
Go Back | New Keyword Search